Literature DB >> 9056700

Evolution of the treatment of hypertension from the 1940s to JNC V.

M Moser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9056700     DOI： 10.1016/s0895-7061(97)00016-2

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   2.689


× No keyword cloud information.
  15 in total

Review 1.  Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy.

Authors:  Domenic A Sica; Henry R Black
Journal:  Curr Hypertens Rep       Date:  2008-08       Impact factor: 5.369

Review 2.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 3.  Management of global risk across the continuum of hypertensive heart disease.

Authors:  Jan Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738

Review 4.  Historical perspectives on the management of hypertension.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-08       Impact factor: 3.738

5.  Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys.

Authors: 
Journal:  Lancet       Date:  2019-07-18       Impact factor: 79.321

6.  Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension.

Authors:  Christina M Salerno; Laura Demopoulos; Robin Mukherjee; Alan H Gradman
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

7.  The treatment of hypertension: a remarkable success story.

Authors:  Marvin Moser; Edward J Roccella
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-11-26       Impact factor: 3.738

8.  Seven decades of progress.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

Review 9.  Systemic delivery of β-blockers via transdermal route for hypertension.

Authors:  Abdul Ahad; Fahad I Al-Jenoobi; Abdullah M Al-Mohizea; Naseem Akhtar; Mohammad Raish; Mohd Aqil
Journal:  Saudi Pharm J       Date:  2014-01-03       Impact factor: 4.330

Review 10.  Rationale for combination therapy as initial treatment for hypertension.

Authors:  Thomas D Giles
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.